Understanding locoregional recurrence in advanced colon cancer

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This observational study investigates the poor outcomes associated with locoregional recurrence in T4 colon cancer. It aims to explore the clinicopathology, metastatic mechanisms, and cancer biology of T4 colorectal cancer, particularly focusing on the hypothesis that peritoneal spreading may be a significant metastatic route. The study will analyze serum epigenetic alterations and cell-free DNA as potential prognostic markers for patients with stage II and III colon cancer who have undergone radical or palliative colectomy.

Why it matters

Who can join: the full rules

* Inclusion Criteria:

  1. Age ≥ 18 years old
  2. Diagnosed as colorectal cancer
  3. Undergo radical colectomy or palliative colectomy, not limited to minimally invasive surgery or open surgery
* Exclusion Criteria:

  1. Age\<18 years old
  2. Pregnancy
  3. Patients with peritoneal dialysis
  4. Patients who are unwilling to undergo colorectal surgery

Where it's running

• National Taiwan University Hospital Hsin-Chu branch
  Hsinchu, Taiwan Recruiting

Study contacts

• Principal investigator: Yu-Tso Liao, MD, PhD — National Taiwan University Hospital Hsin-Chu Branch
• Study coordinator: Yu-Tso Liao, MD, PhD
• Email: G02386@hch.gov.tw
• Phone: 886-3667-7600

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Predicting who will benefit from adjuvant chemotherapy in stage II–III colorectal cancer using tumor splicing patterns

  This project tests whether a tumor splicing signature from surgical tissue can help predict which people with stage II–III colorectal cancer will benefit from adjuvant chemotherapy.

  Recruiting City of Hope Medical Center · Duarte, California · NCT07226115

• Using the Current Together After Cancer (CTAC) website to improve follow-up care for colorectal cancer survivors

  This trial tests whether the CTAC website helps people with resected stage II or III colorectal cancer and a chosen adult supporter get recommended follow-up care that follows guidelines.

  Recruiting at 383 sites Phase 3 SWOG Cancer Research Network · Anchorage, Alaska and 383 other locations · NCT07018869

• Blood test for early detection of colorectal cancer and adenomas

  This study is testing a new blood test to see if it can help find early signs of colorectal cancer and adenomas in people who are already scheduled for a colonoscopy.

  Recruiting at 6 sites City of Hope Medical Center · Monrovia, California and 5 other locations · NCT06342440

• Detecting early onset colorectal cancer using a blood test

  This study is testing a new blood test that looks for specific markers to help find early signs of colorectal cancer in young adults.

  Recruiting at 13 sites City of Hope Medical Center · Duarte, California and 12 other locations · NCT06342401

• Predicting recurrence in stage II/III colorectal cancer after chemotherapy

  This study is trying to create a test that can help predict if people with stage II/III colorectal cancer will have their cancer come back after chemotherapy.

  Recruiting at 4 sites City of Hope Medical Center · Monrovia, California and 3 other locations · NCT06314958

• Assessing minimal residual disease in colorectal cancer using blood tests

  This study is testing if a blood test for cancer DNA can help doctors find out which colorectal cancer patients are at risk of their cancer coming back after surgery and if they need extra treatment.

  Recruiting at 9 sites University of Aarhus · Copenhagen, Capital Region of Denmark and 9 other locations · NCT06076811

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.